All In Biotech

Drug Trial Radar · NCT06449586

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After Allogeneic Hematopoietic Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

Jun 1, 2026

Study completion Jun 1, 2026

Sponsor

Lead sponsor
Ruijin HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of CMV-specific T cell immunity test in prolonged usage of letermovir for avoiding late-onset csCMVi after all-HSCT.

Conditions

  • Hematologic Malignancy

Interventions

  • LetermovirDrug

    letermovir stops when CMI\>1.5

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of late-onset clinical significant CMV (cs-CMV) infectionTime frame: through study completion, an average of 1 year

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital, Shanghai JiaoTong University School of Medicine

    Shanghai, China

  • Shanghai Liquan Hospital

    Shanghai, China

  • Tongji Hospital of Huazhong University of Science and Technology, Wuhan

    Wuhan, Hubei, China

  • Ruijin Hospital of Shanghai Jiaotong University

    Shanghai, Shanghai Municipality, China

  • The First Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.